Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has recommended CRISPR Therapeutics and Vertex Pharmaceuticals. Views expressed on the companies mentioned in this ...

However, as Ben Hargreaves discovers ... pharmaphorum reached out to Vertex Pharmaceuticals to learn more about its general development process and specifically why rare diseases present such ...

Ben Hargreaves finds that a new line of attack ... edging closer to becoming a new non-opioid painkilling option is Vertex Pharmaceuticals’ VX-548 (suzetrigine). The company released Phase ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...